EPS Chuangjian Technology (03860) completed the acquisition of approximately 47.3% of Biotube Co., Ltd.

Zhitong Financial App News, EPS Chuangjian Technology (03860) announced that on November 29, 2023, EPS Innovative Medicine (Japan) Co., a wholly-owned subsidiary of the company. Ltd. (as the buyer) entered into a share transfer agreement with the seller, where the buyer agreed to the acquisition and the seller agreed to sell the shares for sale (approximately 47.3% of the issued share capital of the target company Biotube Co., Ltd.) The cost of the acquisition is 612 million yen (equivalent to approximately HK$318.361 million), which will be disbursed by the buyer in cash.

On November 29, 2023, the target company (as issuer) and EPS Innovative Medicine (Japan) Co., a wholly-owned subsidiary of the company Ltd. (as the subscribing party) entered into a subscription agreement for convertible bonds with a subscription capital of 150 million yen (equivalent to approximately HK$7.8 million).

On January 29, 2024, the second batch of delivery terms were met; the share transfer and subscription of convertible bonds were completed in accordance with the share transfer agreement; the company acquired the target company's shares through its wholly-owned subsidiary (i.e. EPS Innovative Medicine) and converted the convertible bonds into the target company's share capital; and immediately after the conversion of convertible bonds, the company indirectly held 51.0% of the target company's issued share capital, and the target company would become a subsidiary of the company, and the financial results, assets and liabilities of the financial group would be merged into the group Financial statements.